V-NOVA
11.6.2024 10:01:27 CEST | Business Wire | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/
V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia.
V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video industry, such as MPEG-5 LCEVC and VC-6. It has also developed V-Nova PresenZ, a unique volumetric format that enables cinematic 6 Degrees of Freedom (6DoF) immersive experiences for the first time. Recently, V-Nova has demonstrated how its technologies drive substantial efficiencies and unique use cases in AI media indexing, multimodal Generative AI, and Intelligent Edge applications.
V-Nova’s extensive patent portfolio supports a variety of industries, including Entertainment, Social Media, Streaming, Broadcasting, Cloud Gaming, Virtual and Augmented Reality, Industrial Applications, Automotive, Security, and Defence.
“This milestone in V-Nova’s technology portfolio represents a systemic achievement tied to our company structure, strategic focus, and the highly talented individuals we have brought together,” said Guido Meardi, CEO at V-Nova.
Continuous research and development are a cornerstone of V-Nova’s technology roadmap and its resource allocation. The company has been granted 200 patents in the past 12 months alone, with 9 UK patents granted in under 200 days since the filing date. This rapid pace of innovation highlights the quality of its applications and the dedication of its team.
“V-Nova’s success is a result of its company culture, which supports diversity of opinions and encourages collaboration,” said Stergios Poularakis, Head of Advanced R&D at V-Nova. “Our team brings the right people together to interact, innovate, and create something new and exciting.”
V-Nova’s core IP development includes multi-layer and parallel data coding technology that underpins MPEG-5 LCEVC and VC-6. MPEG-5 LCEVC enables users to implement a new data layer onto an existing codec, improving visual quality, reducing energy consumption during the transcoding process, and enhancing compression efficiency. V-Nova’s innovative approach has recently unlocked new virtual reality and mixed reality use cases. The V-Nova PresenZ format enables photo-realistic immersive experiences at scale, with 6 Degrees of Freedom (6DofF) to allow viewers to ‘step inside’ cinematic content. V-Nova technologies also facilitate AI Media Indexing, Machine Vision, and Large Multimodal Models (LMMs) to interact with data like humans, efficiently processing only the necessary resolution and regions of interest while maintaining the entire signal at maximum quality in efficiently compressed form.
V-Nova continues to invest in innovative research and development. Richard Fish, Patent Attorney at V-Nova commented, “Almost 40% of employees at V-Nova are named as inventors on a patent application, making us one of the most innovative companies in the UK, if not the world.”
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, including MPEG-5 LCEVC and VC-6, are based on the innovative use of AI and parallel processing, improve data, video, imaging, and point-cloud compression, and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 1000 international patents, along with a range of software products and solutions. More about V-Nova: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611724561/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press release
NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to en
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press release
£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom